Nika Pharmaceuticals, Inc. (NIKA) Signed a Distribution Agreement for Nigeria
/EIN News/ -- HENDERSON, Nev., July 18, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NIKA) announces the signing of a distribution agreement for the Republic of Nigeria.
The extensive negotiations with I.Conntact-Connect Limited finalized on June 11, 2024 and will allow NIKA to have a strong partner in a key market of 229 million people where recent estimates report a 2.1% national HIV prevalence (approximately 2 million people)1. Under the agreement’s terms, NIKA will receive €1,980 per each set of ITV-1 with two sets necessary for each treatment, which could result in €7.9 billion revenue. More importantly, it will help the battle against a national HIV epidemic, in which 190,950 HIV/AIDS infections are registered each year, with 41,000 cases among children, most of whom do not have access to other therapies.2
NIKA’s CEO Dimitar Savov stated: “Since Nigeria is important for NIKA, in addition to the distribution agreement, we are preparing to open a satellite office there that will serve as a hub for the entire West Africa region.”
About Nika Pharmaceuticals, Inc.
Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA’s goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on www.nikapharmaceuticals.com.
Forward-looking Statement:
This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “expects,” “anticipates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.
________________
1 https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00275-4/fulltext
2 https://www.unicef.org/nigeria/health-hiv
CONTACT Clifford Redekop, Secretary
COMPANY Nika Pharmaceuticals, Inc.
PHONE (702)-326-3615
EMAIL info@nikapharmaceuticals.com
WEB www.nikapharmaceuticals.com
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
